Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Benzinga Newsdesk www.benzinga.com Negative 93.5%

Neg 93.5% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.